CommercialCoverageMedium impact
Gene Expression Profiling for Cutaneous Melanoma (2.04.146)
Blue Shield of California·CA · Dermatology, Oncology, Pathology·Medical Policy
Effective date
Jan 1, 2026
We identified it
Nov 1, 2025
Summary
Blue Shield of California updated their medical policy effective January 1, 2026, declaring all gene expression profiling tests for cutaneous melanoma (including Pigmented Lesion Assay, myPath Melanoma test, and DecisionDx-Melanoma) as investigational and not covered. This means these tests will not be reimbursed by Blue Shield of California for any melanoma-related indication.
Action Required
By January 1, 2026: Billing team must update systems to flag all gene expression profiling tests for cutaneous melanoma as non-covered for Blue Shield of California patients. Providers should be notified that Pigmented Lesion Assay, myPath Melanoma test, and DecisionDx-Melanoma tests are considered investigational and will result in claim denials. Update encounter forms and EMR templates to include coverage warnings for these tests.